ViiV Healthcare to present 23 abstracts from innovative HIV treatment and prevention portfolio at EACS 2023
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced the presentation of key abstracts highlighting the breadth of its approved and investigational medicines at the 19th Annual European AIDS Conference (EACS 2023) being held in Warsaw, Poland from 18-21 October 2023.
Kimberly Smith, M.D., MPH, Head of Research & Development at ViiV Healthcare, said: “Living well with HIV looks different for every individual, and we believe our upcoming presentations at EACS 2023 reflect our commitment and leadership to address the evolving needs of the HIV community. Our latest data from our diverse portfolio and innovative pipeline explore real-world evidence that further evaluate the effectiveness, safety, and tolerability of 2-drug and long-acting regimens; new findings for broadly neutralizing antibodies; and long-term follow-up in heavily treatment-experienced individuals. We look forward to sharing these new insights with the scientific and HIV communities at EACS 2023.”
Key data to be presented at EACS 2023 by ViiV Healthcare will include:
Strengthening clinical and real-world evidence (RWE) across our treatment portfolio: New real-world findings for the long-acting regimen of Vocabria (cabotegravir injection) and Rekambys (rilpivirine long-acting injectable suspension) (CAB+RPV LA) in clinical settings across Europe will be presented at EACS. ViiV Healthcare will share 12-month European findings from the SOLAR study, the first head-to-head, phase IIIb study of the complete long-acting injectable regimen of CAB+RPV LA compared with daily oral Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide [BIC/FTC/TAF]).1
Findings for the 2-drug regimen, Dovato (dolutegravir, lamivudine [DTG/3TC]), will include three-year effectiveness, safety, and tolerability outcomes among people living with HIV in a real-world German cohort and data from a large observational cohort across Europe.2,3 Additional data to be presented will include a review of real-world experience of DTG+3TC in people living with HIV over the age of 50, as well as in treatment-naïve people with a low CD4+ cell count or high viral load at baseline.4
Long-term data in heavily treatment-experienced (HTE) populations: Long-term, five-year data from the phase III BRIGHTE clinical trial, which studied the use of Rukobia (fostemsavir) in heavily-treatment experienced populations with multi-drug resistant HIV-1, will be presented. New data will report on long-term safety and the impact of immune recovery in adults receiving fostemsavir, along with fostemsavir’s impact on immune and inflammation-related biomarkers in these patients.5,6
Advancing new mechanisms of action in HIV research: New phase IIa, proof of concept study findings will be presented from the BANNER study of N6LS (VH3810109), a novel, investigational, broadly neutralizing antibody (bNAb). Safety and tolerability findings following a single IV infusion or subcutaneous injection will be shared.7 N6LS is a component of the company’s ultra-long-acting medicine development strategy, specifically being investigated for dosing intervals of at least every four months.
Here is a list of ViiV Healthcare-sponsored or supported studies being presented at EACS 2023:
3-year outcomes for dolutegravir (DTG) + lamivudine (3TC) in ART-naive and pre-treated people living with HIV-1 (PLHIV) in Germany: real-world data from the German URBAN cohort
Systematic literature review of real-world experience with the 2-drug regimen dolutegravir + lamivudine (DTG + 3TC) in people with HIV-1 (PWH) aged ≥50 years
Real-world effectiveness of dolutegravir + lamivudine (DTG + 3TC) in treatment-naive people with HIV-1 (PWH) and low CD4+ cell count or high viral load at baseline: a systematic literature review
No relevant difference in incident hypertension observed by gender, race, baseline BMI, or other key subgroups through Week 96 among people living with HIV-1 (PLWH) receiving dolutegravir (DTG)-based regimens or comparator antiretroviral therapy (cART) in pooled randomized clinical trials
CARAVEL: evaluation of real-world antiviral effectiveness and sustainability of the 2-drug regimen dolutegravir/lamivudine fixed dose combination (FDC) in treatment-naive adults and pre-treated adults who are virologically suppressed, in routine clinical care, in France: one-year interim analysis results
Pregnancy and neonatal outcomes following prenatal exposure to dolutegravir: the DOLOMITE-EPPICC study
Oral in parallel session
Thursday, October 19 14:50 - 14:55 GMT
Dolutegravir + lamivudine 2-drug regimen is highly effective and well-tolerated in a real-world clinical setting in Europe: data from the COMBINE-2 study
Cabotegravir for Treatment
SOLAR 12-month European results: randomized switch trial of CAB+RPV LA vs. oral BIC/FTC/TAF
I. De Los Santos Gil
Efficacy, safety, and implementation outcomes of cabotegravir + rilpivirine long-acting by country in the Cabotegravir And Rilpivirine Implementation Study in European Locations (CARISEL)
C. J. Oldenbüttel
Cabotegravir + rilpivirine long-acting efficacy and safety outcomes by sex at birth, age, and race: a subgroup analysis of the CARISEL study
Real-world effectiveness of cabotegravir + rilpivirine in virologically suppressed treatment experienced individuals in Europe: data from COMBINE-2 study
Cabotegravir for PrEP
Drivers of discontinuation of oral PrEP within Europe: findings from a real-world survey of PrEP use
Early and durable reductions in soluble CD14 concentrations among treatment-experienced persons with HIV-1 through 96 weeks of fostemsavir treatment in a phase 2b clinical trial
E. R. Wonderlich
Rapid abstract presentation
Friday, October 20
12:15 - 13:15 GMT
Long-term safety and impact of immune recovery in heavily treatment-experienced adults receiving fostemsavir for up to 5 years in the BRIGHTE study
J. M. Llibre
Sustained improvements in biomarkers observed with fostemsavir in heavily treatment-experienced adults with multidrug-resistant HIV-1 from the phase 3 BRIGHTE study through Week 240
Fostemsavir use in the OPERA cohort: immunologic and virologic response
R. K. Hsu
Pipeline: Maturation Inhibitor GSK3640254
Efficacy and safety of the HIV-1 maturation inhibitor GSK3640254 + 2 NRTIs in treatment-naive adults: 24-week results from the phase IIb, dose-range finding DOMINO study
S. R. Joshi
Rapid abstract presentation
Friday, October 20
12:15 - 13:15 GMT
Efficacy and safety of the HIV-1 maturation inhibitor GSK3640254 + dolutegravir as a 2-drug regimen in treatment-naive adults: 24-week results from the phase IIb DYNAMIC study
S. R. Joshi
Rapis abstract presentation
Friday, October 20
12:15 - 13:15 GMT
Pipeline: VH3810109 (N6LS)
Safety and tolerability of VH3810109 (N6LS) among antiretroviral therapy–naive adults living with HIV-1: results from the monotherapy phase of the phase IIa BANNER study
Oral parallel session
Friday, October 20
10:45 - 11:45 GMT
Pharmacokinetics/Pharmacodynamics and virological activity of VH3810109 (N6LS) in antiretroviral-naive viremic adults from the phase IIa BANNER study
A. Y. Edwards
Drivers of satisfaction and health-related quality of life of people living with HIV within Europe: findings from a real-world survey of people living with HIV
Thursday, October 19
07:30 - 08:30 GMT
Patients’ fears and expectations related to HIV infection and its treatment in Poland: a Positive Perspective 2 (PP2) substudy
Modifiable risk factors and their population attributable fractions for TB in people with HIV across Europe
Friday, October 20
10:45 - 11:45 GMT
Dovato is indicated as a complete regimen to treat HIV-1 infection in adults with no antiretroviral (ARV) treatment history or to replace the current ARV regimen in those who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable ARV regimen with no history of treatment failure and no known resistance to any component of Dovato.
Please consult the full Summary of Product Characteristics for all the safety information: Dovato 50 mg/300 mg film-coated tablets
Vocabria (cabotegravir) injection is indicated, in combination with rilpivirine injection, for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with agents of the non-nucleoside reverse transcriptase inhibitors (NNRTI) and integrase inhibitor (INI) class.
Vocabria tablets are indicated in combination with rilpivirine tablets for the short-term treatment of HIV-1 infection in adults who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with agents of the NNRTI and INI class for:
- oral lead in to assess tolerability of Vocabria and rilpivirine prior to administration of long acting Vocabria injection plus long acting rilpivirine injection.
- oral therapy for adults who will miss planned dosing with Vocabria injection plus rilpivirine injection.
Vocabria tablets are only indicated for treatment of HIV-1 in combination with rilpivirine tablets, therefore, the prescribing information for Edurant tablets should also be consulted for recommended dosing.
Please consult the full Summary of Product Characteristics for all the safety information: Vocabria 400mg/600 mg prolonged-release suspension for injectionand Vocabria 30 mg film-coated tablets
Rekambys is indicated, in combination with cabotegravir injection, for the treatment of HIV‑1 infection in adults who are virologically suppressed (HIV-1 RNA < 50 copies/mL) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with, agents of the NNRTI and INI class.
Rekambys should always be co-administered with a cabotegravir injection. The prescribing information for cabotegravir injection should be consulted for recommended dosing.
Rekambys may be initiated with oral lead-in or without (direct to injection).
Please consult the full Summary of Product Characteristics for all the safety information: Rekambys 600mg/900 mg prolonged-release suspension for injection
Rukobia, in combination with other antiretrovirals, is indicated for the treatment of adults with multidrug resistant HIV-1 infection for whom it is otherwise not possible to construct a suppressive anti-viral regimen. Recommended dose is 600mg fostemsavir twice daily.
Please consult the full Summary of Product Characteristics for all the safety information: Rukobia 600 mg prolonged-release tablets
Apretude is a medicine used for preventing sexually transmitted HIV-1 infection (pre-exposure prophylaxis or PrEP) in adults and adolescents weighing at least 35 kg who are at high risk of being infected. It should be used in combination with safer sex practices, such as using condoms. Apretude contains the active substance cabotegravir.
Please consult the full Summary of Product Characteristics for all the safety information: Apretude 600 mg prolonged-release suspension for injection
Trademarks are owned by or licensed to the ViiV Healthcare group of companies.
About ViiV Healthcare
ViiV Healthcare is a global specialist HIV company established in November 2009 by GSK (LSE: GSK) and Pfizer (NYSE: PFE) dedicated to delivering advances in treatment and care for people living with HIV and for people who are at risk of acquiring HIV. Shionogi became a ViiV shareholder in October 2012. The company’s aims are to take a deeper and broader interest in HIV and AIDS than any company has done before and take a new approach to deliver effective and innovative medicines for HIV treatment and prevention, as well as support communities affected by HIV.
For more information on the company, its management, portfolio, pipeline, and commitment, please visit viivhealthcare.com.
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com.
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D 'Risk factors” in the company's Annual Report on Form 20-F for 2022, GSK’s Q2 Results for 2023 and any impacts of the COVID-19 pandemic.
Registered in England & Wales:
ViiV Healthcare Limited
980 Great West Road
ViiV Healthcare Limited
1 De Los Santos Gil I, et al. SOLAR 12-month European results: randomized switch trial of CAB+RPV LA vs. oral BIC/FTC/TAF. Presented at European AIDS Society Conference (EACS). October 2023.
2 Noe S, et al. 3-year outcomes for dolutegravir (DTG) + lamivudine (3TC) in ART-naive and pre-treated people living with HIV-1 (PLHIV) in Germany: real-world data from the German URBAN cohort. Presented at European AIDS Society Conference (EACS). October 2023.
3 Mussini C, et al. Dolutegravir + lamivudine 2-drug regimen is highly effective and well-tolerated in a real-world clinical setting in Europe: data from the COMBINE-2 Study. Presented at European AIDS Society Conference (EACS). October 2023.
4 Letang E, et al. Systematic literature review of real-world experience with the 2-drug regimen dolutegravir + lamivudine (DTG + 3TC) in people with HIV-1 (PWH) aged ≥50 years. Presented at European AIDS Society Conference (EACS). October 2023.
5 Libre J, et al. Long-term safety and impact of immune recovery in heavily treatment-experienced adults receiving fostemsavir for up to 5 years in the BRIGHTE study. Presented at European AIDS Society Conference (EACS). October 2023.
6 Castagna A, et al. Sustained improvements in biomarkers observed with fostemsavir in heavily treatment-experienced adults with multidrug-resistant HIV-1 from the phase 3 BRIGHTE study through Week 240. Presented at European AIDS Society Conference (EACS). October 2023.
7 Leone P, et al. VH3810109 (N6LS) Was Safe and Well Tolerated Among Antiretroviral Therapy-Naïve Adults Living with HIV-1: Results from the Phase IIa BANNER Study. Presented at European AIDS Society Conference (EACS). October 2023.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
ViiV Healthcare enquiries:
Nicola Andre +44 (0) 79 0187 7073 (London)
Rachel Jaikaran +44 (0) 78 2352 3755 (London)
Audrey Abernathy +1 919 605 4521 (North Carolina)
Tim Foley +44 (0) 20 8047 5502 (London)
Sarah Clements +44 (0) 20 8047 5502 (London)
Kathleen Quinn +1 202 603 5003 (Washington DC)
Lyndsay Meyer +1 202 302 4595 (Washington DC)
Alison Hunt +1 540 742 3391 (Washington DC)
Nick Stone +44 (0) 7717 618834 (London)
James Dodwell +44 (0) 20 8047 2406 (London)
Mick Readey +44 (0) 7990 339653 (London)
Josh Williams +44 (0) 7385 415719 (London)
Camilla Campbell +44 (0) 7803 050238 (London)
Steph Mountifield +44 (0) 7796 707505 (London)
Jeff McLaughlin +1 215 751 7002 (Philadelphia)
Frannie DeFranco +1 215 751 4855 (Philadelphia)
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Revolutionizing Water Stewardship – The City of Dire Dawa and Nedamco Africa Unveil Cutting-Edge Water Management Platform Initiative at COP28 | December 9th 2023 | COP28UAE Press Center9.12.2023 10:00:00 CET | Press release
Today, at COP28 in the UAE, the city of Dire Dawa (Ethiopia) Water Supply and Sewerage Authority (DDWSSA) and Nedamco Africa together with its partners Microsoft, Deltares, Hulo.ai and Isle Utilities announced the launch of the “Nedamco Catchment-City-Waste Water Management” (CCW) project for the city of Dire Dawa. The CCW solution by Nedamco Africa and its partners Microsoft, Deltares and Hulo.ai is an integrated technology platform that directly addresses the critical challenges of water losses and inefficient management, prevalent in rapidly urbanizing regions like Dire Dawa. It embodies a holistic approach to water management by harnessing digital twin technology, AI/ML, and satellite imagery to deliver comprehensive monitoring of water infrastructures, detect leakages, and make climate impact predictions with the goal to provide more access to water, more water availability as well as improved water quality. With the deployment of the CCW platform Dire Dawa envisions a transformat
Newmont Announces Successful Early Tender Results for the Exchange Offers and Consent Solicitations9.12.2023 01:51:00 CET | Press release
Newmont Corporation (Newmont or the Company) announced today, in connection with the previously announced offers to exchange (each, an “Exchange Offer” and, collectively, the “Exchange Offers”) any and all outstanding notes (the “Existing Newcrest Notes”) issued by Newcrest Finance Pty Limited, a wholly owned subsidiary of Newmont (“Newcrest Finance” and, together with Newmont, the “Issuers”), for (1) up to $1.65 billion aggregate principal amount of new notes to be issued by the Issuers (the “New Newmont Notes”) and (2) cash, and related consent solicitations (each, a “Consent Solicitation” and, collectively, the “Consent Solicitations”) to adopt certain proposed amendments to each of the indentures governing the Existing Newcrest Notes (the “Existing Newcrest Indentures Amendments”), that the Issuers have received tenders with respect to the aggregate principal amounts of Existing Newcrest Notes set forth below, which constitute the requisite consents needed to adopt the Existing New
Board Named a Leader in Gartner® Magic Quadrant™ for Financial Planning Software8.12.2023 17:18:00 CET | Press release
Board, the global leader for Intelligent Planning Solutions, today announced that it has been named a Leader in the 2023 Gartner Magic Quadrant for Financial Planning Software. The evaluation was based on specific criteria that analyzed Board’s overall Completeness of Vision and Ability to Execute. “We are thrilled to be named a Leader for the second consecutive year. We believe this recognition is indicative of the incredible value and positive impact our Intelligent Planning Solutions bring to global businesses,” said Jeff Casale, CEO of Board. “In today’s uncertain markets, organizations need a trusted enterprise partner to help innovate and enhance their financial planning and analysis processes to plan smarter and succeed faster. Our solution integrates planning processes in a single platform, offering strategy, finance, and operations with real-time analysis and data sharing, to deliver a truly intelligent approach.” A Gartner Magic Quadrant is a culmination of research in a spec
HCLTech Expands Footprint in Romania With New Global Delivery Center in Iași8.12.2023 15:56:00 CET | Press release
HCLTech, a leading global technology company, announced the launch of its new Global Delivery Center (GDC) in Iași, Romania. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231208755841/en/ Mayor of Iași, Mihai Chirica, cuts the inaugural ribbon of HCLTech’s new delivery center with the company’s CEO and MD, C Vijayakumar; its Romania country leader, Iulian Paduraru; and SVP, Shiv Walia. (Photo: Business Wire) The new state-of-the art center in Iași will provide next-generation digital, engineering, cloud and AI solutions. The center expands HCLTech’s presence in Romania and underscores its commitment to the country as part of its nearshore strategy to serve global clients. “This is a significant milestone for HCLTech in Romania as we continue our growth journey and serve our global clients with new capabilities in the latest technologies. We remain committed to our people and local communities and will continue investing in
Michelob Ultra Partners With Lionel Messi to Announce Being Named the Official Global Beer Sponsor of CONMEBOL Copa América USA 2024™8.12.2023 15:00:00 CET | Press release
AB InBev (Brussel:ABI) (BMV:ANB) (JSE:ANH) (NYSE:BUD), the world’s leading brewer, and CONMEBOL (Confederación Sudamericana de Fútbol), the governing body of South American football, will elevate their partnership with Michelob Ultra as the Official Global Beer Sponsor of Copa América USA 2024™. This renewed agreement deepens the company’s longstanding commitment to fans around the globe through the world’s most popular sporting events. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231208607579/en/ Michelob Ultra partners with Lionel Messi to announce being named the Official Global Beer Sponsor of CONMEBOL Copa América USA 2024™ (Photo: Business Wire) Michelob Ultra is proud to also announce that CONMEBOL Copa América champion and global football icon, Lionel Messi, will be a new brand ambassador. He shared his excitement for the news: “I am so proud to join Michelob Ultra for its activations at CONMEBOL Copa América USA 2